Back

3D co-cultures of primary human hepatocytes and Kupffer-like cells to address innate immune responses to rAAV

Gal, I. R.; Arez, F.; Correia, I. P.; Domenici, G.; Fernandes, S.; Silva, G.; Saldanha, I.; Duarte, N.; Freitas, C.; Alves, P. M.; Maier, U.; Coroadinha, A. S.; Du Plessis, F.; Brito, C.

2025-07-11 immunology
10.1101/2025.07.08.663523 bioRxiv
Show abstract

Recombinant adeno-associated viruses (rAAVs) are a platform of choice for gene therapy. However, liver-directed transduction has been hindered by immune responses unpredicted in the preclinical models, resulting in therapy failure. Liver immune responses are strictly regulated by the interactions between hepatocytes and non-parenchymal liver cells, such as Kupffer cells (the liver-resident macrophages) but how rAAVs induce such responses remains largely unknown. Therefore, human models recapitulating such interactions are required to address innate immune responses. Here, we developed a human 3D model to characterize the contribution of hepatocytes and Kupffer cells to the innate immune response. We developed a strategy for the differentiation of Kupffer-like cells from circulating monocytes based on cell-cell contact with primary human hepatocytes. We fine-tuned critical co-culture parameters to obtain a Kupffer-like phenotype while retaining hepatocyte viability and identity. Functional assessment of the differentiated 3D co-cultures showed that the model is responsive to classical pathogen-associated molecular pattern molecules, at a gene expression and secretory level. Moreover, we observed increased proinflammatory cytokine expression and secretion when challenged with a rAAV vector. Our data indicate the suitability of the novel model to investigate hepatocyte-Kupffer cell interactions and address innate immune responses within a human liver microenvironment.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Hepatology
18 papers in training set
Top 0.1%
22.7%
2
Nature Communications
4913 papers in training set
Top 28%
6.4%
3
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
6.4%
4
Molecular Therapy
71 papers in training set
Top 0.7%
3.6%
5
iScience
1063 papers in training set
Top 5%
3.6%
6
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.2%
2.9%
7
Scientific Reports
3102 papers in training set
Top 44%
2.8%
8
Stem Cell Research & Therapy
30 papers in training set
Top 0.2%
2.8%
50% of probability mass above
9
Journal of Controlled Release
39 papers in training set
Top 0.4%
2.6%
10
European Journal of Immunology
57 papers in training set
Top 0.2%
1.8%
11
Cell Reports Medicine
140 papers in training set
Top 3%
1.8%
12
eLife
5422 papers in training set
Top 41%
1.7%
13
Frontiers in Immunology
586 papers in training set
Top 4%
1.7%
14
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 4%
1.7%
15
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.5%
16
PLOS ONE
4510 papers in training set
Top 57%
1.5%
17
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 2%
1.3%
18
Stem Cell Reports
118 papers in training set
Top 0.6%
1.2%
19
Cell Death & Disease
126 papers in training set
Top 1%
1.2%
20
Cytotherapy
14 papers in training set
Top 0.3%
0.9%
21
Molecular Therapy Methods & Clinical Development
13 papers in training set
Top 0.1%
0.9%
22
Advanced Science
249 papers in training set
Top 16%
0.9%
23
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 5%
0.9%
24
Journal of Hepatology
18 papers in training set
Top 0.4%
0.8%
25
Cells
232 papers in training set
Top 7%
0.7%
26
International Journal of Molecular Sciences
453 papers in training set
Top 16%
0.7%
27
PLOS Pathogens
721 papers in training set
Top 10%
0.6%
28
Cell Reports Methods
141 papers in training set
Top 6%
0.6%
29
Journal of Medical Virology
137 papers in training set
Top 5%
0.6%
30
BMC Biology
248 papers in training set
Top 6%
0.6%